Form 4: Hologic Director Nanaz Mohtashami Reports Acquisition of Stock and Stock Options

Director Nanaz Mohtashami reports acquisition of Hologic stock and stock options.

Summary

• On February 26, 2025, Nanaz Mohtashami, a director of Hologic Inc., reported the acquisition of 1,864 shares of common stock and 5,535 non-qualified stock options.
• The common stock was acquired through restricted stock units that vest on the date of the 2026 Annual Meeting of Stockholders.
• The stock options, with an exercise price of $64.36, become exercisable on the date of the 2026 Annual Meeting of Stockholders and expire on February 26, 2035.
• Following the reported transactions, Ms. Mohtashami beneficially owns 4,181 shares of common stock and 5,535 derivative securities.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock transactions by a company director.

Positives

• The acquisition of stock and stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The restricted stock units vest and the options become exercisable on the date of the 2026 Annual Meeting of Stockholders.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in the healthcare industry.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, reflecting confidence from a company director.

Key Dates